Welcome to our dedicated page for ANAPTYSBIO SEC filings (Ticker: ANAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AnaptysBio, Inc. filings document the company’s transition to a royalty management business and its Nasdaq-listed common stock under the symbol ANAB. Recent Form 8-K and 8-K/A filings cover the completed separation of First Tracks Biotherapeutics, related separation and transition services agreements, pro forma financial information, and material-event reporting tied to the new corporate structure.
The filing record also includes disclosures on operating and financial results, Regulation FD materials, stock repurchase authorizations, governance matters, and contract litigation involving the Jemperli Collaboration and Exclusive License Agreement. These documents frame AnaptysBio’s capital structure, collaboration rights, royalty-related business focus, and public-company reporting obligations.
AnaptysBio (NASDAQ:ANAB) filed a routine Form 144 on June 29, 2025, notifying the SEC of a proposed sale of 3,015 common shares valued at approximately $72,269.55 (about $23.96 per share). The shares were originally received as restricted stock on June 15, 2025 and are expected to be sold around June 18, 2025 through Morgan Stanley Smith Barney. The filer reported no other sales in the past three months and affirmed that no undisclosed material adverse information is known. With 29,380,496 shares outstanding, the proposed sale represents a negligible fraction of total equity and does not indicate any material change to AnaptysBio’s operations or financial condition.